Aspergillosis Treatment Market
- 2026 年市場規模
- USD 4.2 Bn
- 2033 年預估規模
- USD 5.9 Bn
- 年複合成長率 CAGR
- 5%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Aspergillosis Treatment Market, By Drug Class (Corticosteroids and Anti-fungal), By Disease Type (Invasive Aspergillosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Allergic Aspergillus Sinusitis, Aspergilloma, and Cutaneous Aspergillosis), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Aspergillosis is a group of diseases that occur from aspergillus infection. Aspergillus is a fungus whose spores are present in the air, but does not normally cause illness. Individuals with damaged lungs, sensitive immune system, and allergies are more prone to aspergillus induced infection. Common aspergillus infections include invasive aspergillosis, non-invasive Allergic Pulmonary Aspergillosis (ABPA), and Chronic Pulmonary Aspergilloma (CPA). Azoles are the only oral drug with anti-aspergillus activity and itraconazole and voriconazole are considered as first-line drugs for chronic pulmonary aspergillosis.
Market Dynamics
Key players operating in the market are focusing on development and approval of novel therapeutics for the treatment of chronic aspergillosis, which is expected to offer a lucrative opportunity to the market players to launch innovative products in the market for the treatment of aspergillosis. For instance, In October 2017, Mylan N.V. launched caspofungin acetate for injection, one of the first generic versions of the U.S. pharma giant Merck's & Co’s Cancidas. It is indicated for invasive aspergillosis in patients who are refractory to or intolerant of other therapies. Furthermore, key companies in the market focusing on growth strategies such as FDA approvals which is expected to drive the growth of the market over forecast period. For instance, In January 2020, PULMATRiX, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Fast Track designation to PUR1900 (Pulmazole). The company's inhaled itraconazole antifungal candidate is developed to treat allergic bronchopulmonary aspergillosis (ABPA) in patients with asthma.
Key features of the study
• This report provides in-depth analysis of the global chronic aspergillosis treatment market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic aspergillosis treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Astellas Pharma Inc., Abbott Laboratories, Pfizer Inc., Pulmocide Ltd., Johnson & Johnson, Mylan N.V., Glenmark Pharmaceuticals, Merck & Co., Inc., Mayne Pharma Group Limited, GlaxoSmithKline plc., PULMATRiX, Inc., F2G Ltd, Teva Pharmaceutical Industries Ltd., and Novartis International AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global chronic aspergillosis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic aspergillosis treatment market
Market Segmentation
• By Drug Class Insights (Revenue, USD Bn, 2021 - 2033)
o Corticosteroids
o Anti-fungal
• By Disease Type Insights (Revenue, USD Bn, 2021 - 2033)
o Invasive Aspergillosis
o Chronic Pulmonary Aspergillosis
o Allergic Bronchopulmonary Aspergillosis
o Allergic Aspergillus Sinusitis
o Aspergilloma
o Cutaneous Aspergillosis
• By Region Insights (Revenue, USD Mn, 2021 - 2033)
o North America
U.S.
Canada
o Latin America
Brazil
Argentina
Mexico
Rest of Latin America
o Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC Countries
Israel
Rest of Middle East
o Africa
South Africa
North Africa
Central Africa
• Key Players
o Abbott Laboratories
o AstraZeneca plc
o Eli Lilly and Company
o GlaxoSmithKline
o Johnson & Johnson Services, Inc.
o Mylan Pharmaceuticals, Inc.
o Novartis AG
o Pfizer, Inc.
o TRakeda Pharmaceutical Company Ltd.
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug Class
Market Snapshot, By Disease Type
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Aspergillosis Treatment Market, By Drug Class, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Corticosteroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Anti-fungal
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
5. Global Aspergillosis Treatment Market, By Disease Type, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Chronic Pulmonary Aspergillosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Allergic Bronchopulmonary Aspergillosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Allergic Aspergillus Sinusitis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Aspergilloma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
o Cutaneous Aspergillosis
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Bn)
6. Global Aspergillosis Treatment Market, By Region, 2021 – 2033, (USD Bn)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2021 - 2033, (USD Bn)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Bn)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
Abbott Laboratories
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
AstraZeneca plc Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Eli Lilly and Company
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
GlaxoSmithKline
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Johnson & Johnson Services, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Mylan Pharmaceuticals, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novartis AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Pfizer, Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Takeda Pharmaceutical Company Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們